Cargando…

Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus()

Hepatitis B virus (HBV) targets the liver and is a major driver for liver cancer. Clinical data suggest that HBV infection is associated with reduced response to treatment with the multi-kinase inhibitor sorafenib, the first available molecularly targeted anti-hepatocellular carcinoma (HCC) drug. Gi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Witt-Kehati, Dvora, Fridkin, Alexandra, Alaluf, Maya Bitton, Zemel, Romy, Shlomai, Amir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2018
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884218/ https://www.ncbi.nlm.nih.gov/pubmed/29524828 http://dx.doi.org/10.1016/j.tranon.2018.02.015

Ejemplares similares

Advances and Challenges in Studying Hepatitis B Virus In Vitro
por: Witt-Kehati, Dvora, et al.
Publicado: (2016)

Aberrant PTEN, PIK3CA, pMAPK, and TP53 expression in human scalp and face angiosarcoma
por: Wan, Huiying, et al.
Publicado: (2021)

Retrieval of olfactory fear memory alters cell proliferation and expression of pCREB and pMAPK in the corticomedial amygdala and piriform cortex
por: Hakim, Marziah, et al.
Publicado: (2022)

Contextual Fear Memory Maintenance Changes Expression of pMAPK, BDNF and IBA-1 in the Pre-limbic Cortex in a Layer-Specific Manner
por: Chaaya, Nicholas, et al.
Publicado: (2021)

Ginsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models
por: Chen, Ying-Jie, et al.
Publicado: (2022)

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis
por: Shlomai, Amir, et al.
Publicado: (2018)

Synergistic Inhibitory Effect of Hyperbaric Oxygen Combined with Sorafenib on Hepatoma Cells
por: Peng, Hai-Shan, et al.
Publicado: (2014)

Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines
por: Haga, Yuki, et al.
Publicado: (2017)

Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomes—A Preliminary Study
por: Bartos, Adrian, et al.
Publicado: (2022)

Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib
por: Weng, Xie, et al.
Publicado: (2019)

Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment
por: Bieniek, Adam, et al.
Publicado: (2021)

α‐Fetoprotein fragment synergizes with sorafenib to inhibit hepatoma cell growth and migration and promote the apoptosis
por: Wang, Qiujiao, et al.
Publicado: (2022)

MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression
por: Wan, Zhong, et al.
Publicado: (2020)

Hepatitis C virus Core overcomes all-trans retinoic acid-induced apoptosis in human hepatoma cells by inhibiting p14 expression via DNA methylation
por: Kwak, Juri, et al.
Publicado: (2017)

Facile Fabrication of Reduction-Responsive Supramolecular Nanoassemblies for Co-delivery of Doxorubicin and Sorafenib toward Hepatoma Cells
por: Xiong, Qingqing, et al.
Publicado: (2018)

Interferon alpha regulates MAPK and STAT1 pathways in human hepatoma cells
por: Zhao, Lan-Juan, et al.
Publicado: (2011)

Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
por: Zheng, Ning, et al.
Publicado: (2019)

Evidence of MAPK–JNK1/2 activation by hepatitis E virus ORF3 protein in cultured hepatoma cells
por: Parvez, Mohammad Khalid, et al.
Publicado: (2014)

TARBP2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
por: Lai, Hui‐Huang, et al.
Publicado: (2019)

A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib
por: Pietrobono, Silvia, et al.
Publicado: (2021)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

Child–Pugh Score and ABCG2-rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib
por: Huang, Po-Han, et al.
Publicado: (2022)

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
por: Tan, Wenliang, et al.
Publicado: (2018)

Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma
por: Shi, Hewen, et al.
Publicado: (2023)

Contribution á l’analyse des premiéres données de l’expérience CMS au LHC.
por: Alaluf, David
Publicado: (2017)

The Inhibitory Effects of Recombinant Hespintor Combined with Sorafenib on Transplanted Human Hepatoma in Nude Mice, and Transcriptional Regulation of Hespintor Based on RNA-Seq
por: Lun, Yong-Zhi, et al.
Publicado: (2021)

hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway
por: Shen, Jing, et al.
Publicado: (2020)

Tanshinone IIA promotes vascular normalization and boosts Sorafenib’s anti-hepatoma activity via modulating the PI3K-AKT pathway
por: Qin, Chengdong, et al.
Publicado: (2023)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
por: Yang, Xiao-Dong, et al.
Publicado: (2021)

CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling
por: Chen, Zibo, et al.
Publicado: (2022)

Zerumbone suppresses the potential of growth and metastasis in hepatoma HepG2 cells via the MAPK signaling pathway
por: Lv, Tao, et al.
Publicado: (2018)

LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2020)

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
por: Zhu, Qiankun, et al.
Publicado: (2020)

Sorafenib Inhibits Lymphoma Xenografts by Targeting MAPK/ERK and AKT Pathways in Tumor and Vascular Cells
por: Carlo-Stella, Carmelo, et al.
Publicado: (2013)

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
por: Shen, Y-C, et al.
Publicado: (2013)

An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells
por: Tang, Shuyao, et al.
Publicado: (2016)

CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death
por: Ding, Bisha, et al.
Publicado: (2021)

Effectiveness of Sorafenib in Hepatic Hemangioma
por: Tiwari, Prateek, et al.
Publicado: (2017)

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours
por: Paton, Emily L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lj1362581aqk398i5vbrgreddn